EUVIMEDEUVIMED entdecken
Open Access

Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes

Marc P Bonaca iD, Andrei-Mircea Catarig, Yasemin Hansen, Kim Houlind iD, Chethana Kalmady Ramesh, Bernhard Ludvik, Joakim Nordanstig iD, Neda Rasouli iD, Harald Sourij iD, Subodh Verma iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvae071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Marc P Bonaca und 9 weiteren Autor:innen. Beteiligte Einrichtung: CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemic control, reduce body weight, and reduce the risk of major adverse cardiovascular events in people with atherosclerotic cardiovascular disease and type 2 diabetes (T2D). Methods and results STRIDE (NCT04560998) is a randomized, placebo-controlled, double-blind phase 3b trial evaluating 1 mg once-weekly subcutaneous semaglutide (GLP-1 RA) vs. placebo, in people with symptomatic PAD (Fontaine IIa claudication) and T2D. Eligible participants were ≥18 years, had haemodynamically stable PAD, had no planned intervention, and were not receiving a GLP-1 RA. The primary endpoint is change in maximum walking distance on a constant-load treadmill (CLT). Secondary endpoints include quality of life and cardiometabolic assessments. A total of 792 participants were randomized in 20 countries. Participants’ median age was 68 and median T2D duration 12 years. Risk factors included 25.6% current smokers, 87.9% with hypertension, and 42.7% with coronary heart disease. The mean BMI was 29.6 kg/m2 and the mean HbA1C was 7.3%. Participants exhibited baseline functional impairment with a median maximum walking distance of 186 m on a CLT.

Conclusion

STRIDE has enrolled participants with symptomatic PAD and T2D, frequent risk factors and comorbidities, and functional impairment. The trial will provide evidence for the functional outcomes with semaglutide in people with PAD and T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsIncretinsIntermittent ClaudicationPeripheral Arterial DiseaseAgedFemaleHumansMaleMiddle AgedBiomarkersDouble-Blind MethodExercise ToleranceGlucagon-Like Peptide-1 Receptor AgonistsInjections, SubcutaneousQuality of LifeRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeWalk TestGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP1 agonistMaximal walking distancePADPeripheral artery diseaseSemaglutide

Substanzen

BiomarkersBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsIncretinsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, CO, USA.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Department of Vascular Surgery, Lillebaelt Hospital.
  • Department of Regional Health Research, University of Southern Denmark, Denmark.
  • Novo Nordisk GBS India, Bangalore, India.
  • 1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders Landstrasse Clinic, Vienna, Austria.

ORCID-Profile: Marc P Bonaca, Kim Houlind, Joakim Nordanstig, Neda Rasouli, Harald Sourij, Subodh Verma

Förderung

  • Novo Nordisk

Zitieren

APA

Bonaca, M. P., Catarig, A. M., Hansen, Y., Houlind, K., Ramesh, C. K., Ludvik, B., Nordanstig, J., Rasouli, N., Sourij, H., & Verma, S. (2025). Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae071

Vancouver

Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, et al. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae071

BibTeX
@article{Bonaca2025,
  author = {Bonaca, Marc P and Catarig, Andrei-Mircea and Hansen, Yasemin and Houlind, Kim and Ramesh, Chethana Kalmady and Ludvik, Bernhard and Nordanstig, Joakim and Rasouli, Neda and Sourij, Harald and Verma, Subodh},
  title = {Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvae071}
}
Kostenlos starten →